Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Selexipag in Stable PAH
NCT03187678Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Number of Participants With at Least One Adverse Event (AE), Number of Participants With Prostacyclin-associated Adverse Events and 3 more. Started Dec 2017; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03187678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187678.